What's Happening?
Precision BioSciences will present new clinical biopsy data from its Phase 1 ELIMINATE-B trial at the European Association for the Study of the Liver (EASL) Congress 2026. The trial evaluates PBGENE-HBV, a gene editing therapy for chronic hepatitis B,
demonstrating elimination and inactivation of cccDNA. This marks the first evidence of such an effect in liver biopsies, positioning PBGENE-HBV as a potentially curative treatment. The therapy has been granted Fast Track designation by the FDA, highlighting its significance in addressing a high unmet medical need.
Why It's Important?
The presentation of PBGENE-HBV data is a significant milestone in the development of gene editing therapies for chronic hepatitis B, a condition with limited treatment options. The ability to eliminate cccDNA could lead to a cure, transforming the treatment landscape and improving patient outcomes. The Fast Track designation by the FDA underscores the therapy's potential impact, accelerating its development and regulatory review process. Successful outcomes could pave the way for broader applications of gene editing in treating infectious diseases.
What's Next?
Precision BioSciences will continue to advance the ELIMINATE-B trial, exploring different dose levels and administration schedules. The company aims to gather more data to support future regulatory submissions and potential commercialization. Ongoing engagement with the FDA and other stakeholders will be crucial in advancing PBGENE-HBV towards market approval and availability to patients.
